# Sample Report

**Sample Report, 167351**

---

## Specimen Details
- **Date collected:** 01/29/2019 0000 Local
- **Date received:** 01/30/2019
- **Date entered:** 01/30/2019
- **Date reported:** 02/01/2019 0000 ET

## Patient Details
- **DOB:** 01/10/1980
- **Age:** 039/00/19
- **Gender:** F
- **SSN:**
- **Patient ID:**

---

## Ordered Items

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA B*58:01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>B*15:02:01</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>B*58:01:01:01</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

The HLA-B*58:01 allele WAS DETECTED in this individual. HLA-B*58:01 is associated with a significantly increased risk of allopurinol related severe cutaneous adverse drug reaction (SCAR) including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).

**REFERENCES**


The following alleles could not be ruled out:

| B* | 58:01:01:01/58:01:01:03 |

HLA allele interpretation for all loci based on IMGT/HLA database version 3.31.0

**HLA Lab CLIA ID Number 34D0954530**

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

**HLA Methodology**

HLA results were obtained using sequence based typing (SBT),
<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>sequence specific oligonucleotide probes (SSOP), and/or sequence specific primers (SSP) as needed to obtain the required resolution. Please contact HLA Customer Service at 1-800-533-1037 if you have any questions. Director of HLA Laboratory Dr George C Maha, PhD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 800-762-4344
**Sample Report, 167351**

**Patient Details**
- **DOB:** 01/10/1980
- **Age (y/m/d):** 039/00/19
- **Gender:** F
- **SSN:**
- **Patient ID:**

**Specimen Details**
- **Date collected:** 01/29/2019 0000 Local
- **Date received:** 01/30/2019
- **Date entered:** 01/30/2019
- **Date reported:** 02/01/2019 0000 ET

**Physician Details**
- **Ordering:**
- **Referring:**
- **ID:**
- **NPI:**

**Ordered Items**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HLA B*58:01</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-B</td>
<td>B*15:01:01:01:01</td>
<td></td>
<td></td>
<td></td>
<td>01</td>
</tr>
<tr>
<td></td>
<td>This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-B</td>
<td>B*-</td>
<td></td>
<td></td>
<td></td>
<td>01</td>
</tr>
<tr>
<td></td>
<td>This specimen is NEGATIVE for the HLA-B<em>58:01 allele. The HLA-B</em>58:01 allele, associated with allopurinol related severe cutaneous adverse drug reaction (SCAR) including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) was not detected in this individual. A negative result for HLA-B<em>58:01 does not preclude the development of an allergic response to allopurinol. The absence of the HLA-B</em>58:01 genotype result should not substitute for appropriate clinical vigilance and patient management in patients using allopurinol.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**REFERENCES**
- HLA allele interpretation for all loci based on IMGT/HLA database version 3.31.0
- HLA Lab CLIA ID Number 34D0954530

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved.
by the Food and Drug Administration. HLA Methodology

HLA results were obtained using sequence based typing (SBT), sequence specific oligonucleotide probes (SSOP), and/or sequence specific primers (SSP) as needed to obtain the required resolution. Please contact HLA Customer Service at 1-800-533-1037 if you have any questions.

Director of HLA Laboratory
Dr George C Maha, PhD

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 800-762-4344